Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Total Liabilities (2023 - 2025)

Compass Therapeutics' Total Liabilities history spans 3 years, with the latest figure at $22.8 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 50.28% year-over-year to $22.8 million; the TTM value through Dec 2025 reached $22.8 million, up 50.28%, while the annual FY2025 figure was $22.8 million, 50.28% up from the prior year.
  • Total Liabilities for Q4 2025 was $22.8 million at Compass Therapeutics, up from $21.6 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $23.5 million in Q2 2025 and bottomed at $4.1 million in Q1 2024.
  • The 3-year median for Total Liabilities is $11.8 million (2023), against an average of $14.2 million.
  • The largest annual shift saw Total Liabilities tumbled 67.88% in 2024 before it surged 418.67% in 2025.
  • A 3-year view of Total Liabilities shows it stood at $8.3 million in 2023, then soared by 81.96% to $15.2 million in 2024, then surged by 50.28% to $22.8 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Total Liabilities are $22.8 million (Q4 2025), $21.6 million (Q3 2025), and $23.5 million (Q2 2025).